Personalised mRNA vaccine shows promise in preventing melanoma recurrence
A new personalised mRNA vaccine combined with immunotherapy has significantly extended cancer-free periods for high-risk melanoma patients in a clinical trial, marking a potential breakthrough in cancer treatment.
A groundbreaking clinical trial has demonstrated that a personalised mRNA vaccine, combined with an existing immunotherapy drug, can significantly reduce the risk of melanoma recurrence in high-risk patients. The vaccine, developed by Merck and Moderna, was administered to over 1,000 patients with stage two, three, or four melanoma after surgery. Early results indicate that the combination therapy prolonged the time patients remained cancer-free and lowered the likelihood of the disease spreading to other organs compared to the immunotherapy drug alone.
## How the personalised vaccine works
The vaccine, named Intismeran, is tailored to each patient's tumour. Scientists extract a small sample of the tumour, sequence its DNA, and use mRNA technology-similar to that used in some Covid-19 vaccines-to target specific mutations in the cancer cells. This approach trains the immune system to recognise and attack any remaining tumour cells, providing a customised defence against recurrence.
The trial results have generated excitement among cancer researchers, though experts caution that the findings are still preliminary. Dr. Talisia Quallo, head of prevention and early detection at Cancer Research UK, described the research as promising but stressed the need for further review of the interim data. She emphasised the importance of continued funding for such studies to expand personalised treatment options for cancer patients.
## Broader implications and future research
Dr. Lennard Lee, a consultant medical oncologist at the University of Oxford, noted that while the results are encouraging for melanoma patients, they also provide evidence that personalised cancer vaccines can work in principle. The success of this trial has prompted Merck and Moderna to explore similar vaccines for other cancers, including lung, bladder, and kidney cancers.
Stephane Bancel, CEO of Moderna, called the findings a pivotal moment in cancer research. However, the treatment must still undergo regulatory approval before becoming widely available, including a separate approval process for NHS use. The trial's full results have not yet been published or peer-reviewed, leaving some questions unanswered about the long-term effectiveness of the vaccine.
The news has already had a significant impact, with shares in both Moderna and Merck rising following the announcement. While the results are a major step forward, experts remain cautious, awaiting further data to confirm the vaccine's long-term benefits.
